Address: 875 Pacific Highway, Pymble NSW 2073,Australia
Tel: +61 (0) 2 9391 6000
Web: http://www.bayer.com.au/scripts/pages/en/index.php
Bayer Australia is part of an international, research-based group with major businesses in health care, nutrition and high-tech materials.
Employing over 108,000 people worldwide, and 840 in Australia/New Zealand, the Bayer Group has a portfolio of over 5,000 products and operations in nearly all countries of the globe. Worldwide operations are managed from Group headquarters in Leverkusen, Germany.
Bayer Australia aims for technological leadership in its core activities. Fundamental to business is the acknowledgment that technical and commercial expertise involves a responsibility to work for the common good and contribute to sustainable development.
In 2008 the Bayer Group recorded sales of EUR 32.9 billion, and invested heavily in research and development. Bayer’s operations in Australia and New Zealand generated AU$728 million ($NZ868 million) in revenue in 2008.
Antibiotic, Cardiovascular, Hormone replacement therapy, Oncology
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
See our Cookie Privacy Policy Here
